AMG 224

Drug Profile

AMG 224

Alternative Names: AMG-224

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 01 Nov 2015 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Australia (IV)
  • 09 Sep 2015 Preclinical trials in Multiple myeloma in USA (IV)
  • 09 Sep 2015 Amgen plans a phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (NCT02561962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top